Profile of:

Giuseppe Lopalco


WORK EXPERIENCE: MD Resident in Rheumatology, University of Bari “Aldo Moro”, School of Medicine, School of Rheumatology from June 2009 to 17th June 2014 Assistant Research Fellow at Rheumatology Unit, University of Siena from September 2013 to December 2013 Rheumatology Consultant at Rheumatology Unit of University of Bari “Aldo Moro”, Bari (IT) from Dicember 2014 to June 2021 Associate Professor of Rheumatology at Rheumatology Unit of University of Bari “Aldo Moro”, Bari (IT) since 3rd June 2021 EDUCATION AND TRAINING: October 2008 Graduation in Medicine University of Bari “Aldo Moro”, Bari, Italy October 2014 Specialization in Rheumatology at University of Bari “Aldo Moro” May 2018 Master Degree “Clinical and Theoretical short Master in Rheumatology” at University of Bari “Aldo Moro AREAS OF RESEARCH/INTEREST: Spondylarthritis, Behçet’s disease, Autoinflammatory diseases, Systemic Vasculitis, Rheumatoid Arthritis, Rare Rheumatic diseases, Ocular inflammatory diseases, Idiopathic pericarditis WORKING RELATIONSHIP: Research Center of Systemic Autoinflammatory Diseases and Behçet Disease Clinic, University of Siena (Professor Luca Cantarini) - Research group on pediatric rheumatic diseases, (mainly Behcet disease and systemic juvenile idiophatic arthritis) coordinated by Professor Rolando Cimaz, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. - Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, United States (Professor Valentino Stella) - Coordinating center of the European Reference Network ReCONNET for rare and complex connective tissue diseases (http://reconnet.ern-net.eu/) coordinated by Professor Marta Mosca, University of Pisa and Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. - Research group on Idiopathic inflammatory myopathy coordinated by Professor Ingrid Lundberg, Karolinska Institute in Stockholm, Sweden. - Research group of the Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence (Professor Emmi Giacomo - Professor Domenico Prisco). - Research group on recurrent Idiopathic Pericarditis coordinated by Prof Massimo Imazio (University Cardiology, AOU City of Health and Science of Turin, Italy) and Professor Antonio Brucato Fatebenefratelli-Sacco, University of Milan, Italy. HONOUR AND AWARDS: Professorship at University of Bari “Aldo Moro” – Rheumatology, Medicine School since 2021 - Grant provided by the Italian Society of Rheumatology (SIR) to young researchers for best poster presented at the 17th International Conference on Behçet’s Disease, Matera, September 2016. - Towards EULAR 2017” bursary provided by the Italian Society of Rheumatology (SIR) to young researchers for best presentation at the 53rd National Conference of the Italian Society of Rheumatology (SIR, Rimini, November 2016. - Grant provided by the Italian Society of Rheumatology (SIR) to young researchers for best oral presentation on PsA (Antonio Spadaro prize) the 55th National Conference of the Italian Society of Rheumatology - Grant provided by the Italian Society of Rheumatology (SIR) to young researchers for best oral presentation on “Predictors of long-term clinical response in patients with Behcet's disease-related uveitis treated with infliximab and adalimumab” the 55th National Conference of the Italian Society of Rheumatology. - Grant provided by the Italian Society of Rheumatology (SIR) to young researchers for best oral presentation on PsA (Antonio Spadaro prize) the 58th National Conference of the Italian Society of Rheumatology (SIR, Rimini, November 2021). - Coinvestigator for the University of Bari: "Role of TNF-alpha blocking agents in the treatment of Behçet disease: a prospective multicentre randomized controlled trial”. 2016 funding (€ 300,000.00) from the Italian MedicinesAgency (AIFA) after peer review evaluation. - Principal Investigator for the University of Bari for the development of an international registry aimed at collecting and evaluating clinical and therapeutic data of patients suffering from monogenic and polygenic autoinflammatory diseases (AIDA Project). - Associate Editor for the journal Frontiers in Immunology – Autoimmune and Autoinflammatory section (IF 7.561) - Associate Editor for the journal Orphanet Journal of Rare Diseases – Adult rheumatological diseases section. OTHER MEMBERSHIPS: Italian Society of Rheumatology (SIR) - Autoinflammatory Diseases Working Group of the Italian Society of Rheumatology - AIDA Network Academy

Full name: Giuseppe Lopalco

Current country: Italy

Membership level: Associate

Type of membership: Member

Number of publications: 11

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors (2022)
https://pubmed.ncbi.nlm.nih.gov/34987092/

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab (2022)
https://pubmed.ncbi.nlm.nih.gov/35833126/

Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA (2021)
https://pubmed.ncbi.nlm.nih.gov/32755721/

High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry (2021)
https://pubmed.ncbi.nlm.nih.gov/33864158/

Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31652315/

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/32317863/

Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast (2020)
https://pubmed.ncbi.nlm.nih.gov/32383167/

Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. (2019)
https://pubmed.ncbi.nlm.nih.gov/31025925/

Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings (2018)
https://pubmed.ncbi.nlm.nih.gov/30079593/

Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. (2018)
https://pubmed.ncbi.nlm.nih.gov/30109794/

Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study (2017)
https://pubmed.ncbi.nlm.nih.gov/27974094/